Regeneus Ltd. (AU:CMB) has released an update.
Regeneus Ltd., under its entity name Cambium Bio Limited, has announced the cessation of 3.8 million securities due to the expiry of options or other convertible securities without exercise or conversion as of May 11, 2024. The news released on July 9, 2024, is essential for investors tracking the company’s capital structure and potential market implications.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.
